Endologix Inc. (NASDAQ:ELGX) has been assigned a $11.00 price target by research analysts at Oppenheimer Holdings Inc. in a research note issued to investors on Monday. The firm presently has a “buy” rating on the stock. Oppenheimer Holdings Inc.’s target price would indicate a potential upside of 46.08% from the company’s current price.

A number of other analysts have also recently commented on the stock. Leerink Swann set a $8.00 price objective on shares of Endologix and gave the company a “hold” rating in a research report on Saturday. BMO Capital Markets lowered shares of Endologix from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $14.00 to $9.50 in a research note on Wednesday, November 16th. Guggenheim lowered shares of Endologix from a “buy” rating to a “neutral” rating in a research note on Wednesday, November 16th. Canaccord Genuity lowered shares of Endologix from a “buy” rating to a “hold” rating and reduced their target price for the stock from $13.50 to $7.50 in a research note on Wednesday, November 16th. Finally, JPMorgan Chase & Co. lowered shares of Endologix from an “overweight” rating to a “neutral” rating and reduced their target price for the stock from $14.00 to $10.00 in a research note on Wednesday, November 16th. Eight equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $11.77.

Analyst Recommendations for Endologix (NASDAQ:ELGX)

Endologix (NASDAQ:ELGX) opened at 7.53 on Monday. The company’s market capitalization is $622.66 million. The stock has a 50 day moving average price of $10.75 and a 200-day moving average price of $12.13. Endologix has a 1-year low of $6.22 and a 1-year high of $14.49.

Endologix (NASDAQ:ELGX) last released its quarterly earnings data on Tuesday, November 1st. The company reported ($0.18) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.15) by $0.03. Endologix had a negative net margin of 78.53% and a negative return on equity of 39.12%. The firm earned $52.12 million during the quarter, compared to the consensus estimate of $51.83 million. During the same quarter in the prior year, the company earned ($0.16) EPS. Endologix’s quarterly revenue was up 36.3% on a year-over-year basis. Equities analysts predict that Endologix will post ($0.71) earnings per share for the current year.

In other news, Director Guido J. Neels bought 13,000 shares of the company’s stock in a transaction dated Friday, November 18th. The shares were bought at an average cost of $7.69 per share, with a total value of $99,970.00. Following the acquisition, the director now owns 41,380 shares in the company, valued at $318,212.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.90% of the stock is currently owned by insiders.

Several large investors have recently modified their holdings of the stock. Elk Creek Partners LLC boosted its position in Endologix by 14.7% in the second quarter. Elk Creek Partners LLC now owns 1,482,885 shares of the company’s stock valued at $18,477,000 after buying an additional 190,453 shares in the last quarter. Brown Capital Management LLC bought a new position in Endologix during the second quarter valued at $60,477,000. Stephens Inc. AR boosted its position in Endologix by 16.2% in the second quarter. Stephens Inc. AR now owns 93,860 shares of the company’s stock valued at $1,169,000 after buying an additional 13,053 shares in the last quarter. SG Americas Securities LLC bought a new position in Endologix during the second quarter valued at $1,098,000. Finally, Rothschild Asset Management Inc. bought a new position in Endologix during the second quarter valued at $364,000.

ILLEGAL ACTIVITY WARNING: This report was first published by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are accessing this report on another website, it was stolen and republished in violation of U.S. & international copyright legislation. The legal version of this report can be accessed at https://www.thecerbatgem.com/2016/11/23/endologix-inc-elgx-pt-set-at-11-00-by-oppenheimer-holdings-inc.html.

Endologix Company Profile

Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.

5 Day Chart for NASDAQ:ELGX

Receive News & Stock Ratings for Endologix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix Inc. and related stocks with our FREE daily email newsletter.